Technical impact
Farmasimplex healthcare integration modules fail to validate TLS certificates, allowing an attacker who can intercept traffic to impersonate trusted services. This flaw enables a man‑in‑the‑middle attack that can result in the disclosure or modification of sensitive healthcare data. The weakness is an improper record or data validation vulnerability, specifically CWE‑295.
Affected Systems
The affected components are the Farmasimplex healthcare integration modules developed by CIPCarbone. No specific affected versions are listed, so all current installations of these modules are considered vulnerable.
Risk and Exploitability
The CVSS score of 7.1 indicates a moderate‑to‑high severity. An exploiter would need the ability to intercept or redirect traffic between the client and the integration service, a capability usually available to attackers within the same network or on compromised endpoints. Because exposure does not grant code execution and there is no disclosed exploit technique, the likelihood of immediate exploitation is relatively low, but the potential damage to confidentiality and integrity is significant. The vulnerability is not listed in the CISA KEV catalog and EPSS information is unavailable.